Caribou Biosciences, Inc. (CRBU) — Analyst outlook / Analyst consensus target is. Based on 9 analyst ratings, the consensus is bullish — 9 Buy.
The consensus price target is $7.00, representing an upside of 230.2% from the current price $2.12.
Analysts estimate Earnings Per Share (EPS) of $-1.66 and revenue of $0.01B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.65 vs est $-1.66 (beat +0.5%). 2025: actual $-1.59 vs est $-1.59 (missed -0.2%). Analyst accuracy: 100%.
CRBU Stock — 12-Month Price Forecast
$7.00
▲ +230.19% Upside
Average Price Target
Based on 9 Wall Street analysts offering 12-month price targets for Caribou Biosciences, Inc., the price target is $7.00.
The average price target represents a +230.19% change from the last price of $2.12.
CRBU Analyst Ratings
Buy
Based on 9 analysts giving stock ratings to Caribou Biosciences, Inc. in the past 3 months
EPS Estimates — CRBU
100%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.65
vs Est –$1.66
▲ 0.5% off
2025
Actual –$1.59
vs Est –$1.59
▼ 0.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — CRBU
91%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.010B
vs Est $0.010B
▼ 2.7% off
2025
Actual $0.011B
vs Est $0.009B
▲ 15.9% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
